NeuroDerm Makes Progress On Simplified Path To Parkinson's Approval

 
• By Mandy Jackson

NeuroDerm Ltd. reported Phase II results for its drug-device combination product ND0612 that reinforce its ability to fill a gap in the treatment of advanced Parkinson's disease, and it could be on the market in the US in less than three years if the company is able to stay on its revised development path.

Human brain illustrated with millions of small nerves - Conceptual 3d render

More from Strategy

More from Business